This study was undertaken to investigate the potential effect of tamoxifen and amygdalin in mammary carcinoma induced in mice. Fifty female albino mice, 4-6 weeks old age, were divided into five equal groups: group I (control normal) administrated no drugs; group II (carcinogenic group) administrated 7,12-dimethylbenz[a]anthracene (DMBA) dissolved in sesame oil (50 mg/kg b.wt) once a weak orally for 4 weeks; group III (tamoxifen treated group) given tamoxifen (50 mg/kg b.wt/day) orally for 4 weeks after induction of mammary cancer; group IV (amygdalin treated group) treated with amygdalin (0.6 mg/kg b.wt/day) for 4 weeks after induction of mammry carcinoma; group V (tamoxifen + amygdalin treated goup) administrated tamoxifen as in group (III) with amygdalin as in group (IV). The obtained results exhibited that DMBA-induced mammary carcinomas caused a significant increase in serum progesterone and mammary tissue L-malondialdehyde (L-MDA) concentrations, with significant decrease in total antioxidant capacity (TAC) as compared to the control group. However, the administration of tamoxifen and amygdalin alleviate DMBA-induced mammary carcinomas through decreasing serum progesterone and L-MDA concentrations, along with increasing TAC concentration in mammary tissue. Additionally, hematological parameters of tamoxifen and amygdalin-treated mice displayed a significant increase compared to mammaty cancer treated mice. Thus, it can be concluded that tamoxifen with amygdalin may be successful in the treatment of mammary carcinoma as well as improvement of oxidative stress of mammary carcinoma tissue.